Key takeaway: Management reported that FY26 was a significant year for SMS Pharmaceuticals Limited, achieving a 13% revenue growth to INR 887 crores, with Q4 revenue at INR 238 crores. EBITDA margins improved to 20%, driven by backward integration and a favorable product mix. The company noted a 47% increase in PAT for FY26, reaching INR 102 crores. Management highlighted ongoing investments in capacity expansion and product registrations, with a goal of 15% revenue growth for FY27. They emphasized the importance of their anti-inflammatory and ARV segments, while also addressing challenges in the anti-diabetic segment. The company plans to maintain a robust product pipeline with multiple filings in the coming years. Management expressed optimism about future growth, contingent on external factors stabilizing, particularly in logistics and supply chains.

Key takeaway: The investor presentation for SMS Pharmaceuticals Limited reported a strong performance for the third quarter and nine months ended December 31, 2025. Revenue increased by 21% year-over-year, driven by significant volume growth in key APIs. The EBITDA margin rose to above 20%, reflecting a 31% year-over-year increase, while profit after tax (PAT) reached ₹23.47 crore, up 29% year-over-year. The company is progressing well with a ₹280 crore capital expenditure program, on track for completion by FY27. Management set a goal of achieving 20% revenue growth for FY26, with EBITDA margins of 20%. The presentation highlighted the company's diversified product portfolio and strong presence in regulated markets, emphasizing its strategic focus on R&D and operational efficiencies.